Overview

Psilocybin for Treatment of Obsessive Compulsive Disorder

Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This study will evaluate whether psilocybin, a hallucinogenic drug, improves symptoms of obsessive compulsive disorder (OCD), whether it is safely tolerated as treatment of OCD, and will investigate the mechanisms by which it works.
Phase:
Phase 1
Details
Lead Sponsor:
University of Arizona
Treatments:
Lorazepam
Psilocybin
Psilocybine